A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...

The successful clinical validation of AlloHeme represents a key milestone in CareDx's Transplant+ strategy, expanding the Company's precision medicine capabilities into cell therapy, hematology, and ...

CareDx, Inc. ? The Transplant Companytm, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high?value healthcare solutions ...

Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...

A major study led by the University of Hertfordshire has shown how linking care home data with NHS and social care records can improve residents' lives, strengthen policy decision-making and ensure ...

Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety ...

Adtalem Global Education changed its name to Covista last week, a move the company says signals its ambitions in addressing ...

Q4 2025 Management View CEO Brian Goff emphasized the company's 2026 strategic priorities, stating, "we're focused on executing a high-impact launch of AQVESME for the treatment of thalassemia in the ...

CMS appears to have made even more changes to its antipsychotic quality measure without advance notice, experts say. One consequence could be lower star ratings of which providers are unaware.

Becton, Dickinson and Company (NYSE:BDX) Q1 2026 Earnings Call Transcript February 9, 2026 Becton, Dickinson and Company beats earnings expectations. Reported EPS is $2.91, expectations were $2.81.

Detailed price information for Takeda Pharmaceutical Ltd ADR (TAK-N) from The Globe and Mail including charting and trades.

Ascentage Pharma will be conducting a multicenter, open-label Phase I study designed to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of APG-3288 in ...